ArticleSurgical endoscopy2026
Effects of laparoscopic splenectomy and azygoportal disconnection on liver reserve function for cirrhosis patients: a 1-year prospective study.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05325437 (The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on Liver Reserve Function for Cirrhosis Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundIn Asia, laparoscopic splenectomy and azygoportal disconnection (LSD) is a primary and effective treatment for patients with cirrhotic portal hypertension. While LSD is widely recognized to improve liver function in cirrhosis, its specific effect on liver reserve function remains underexplored. This prospective study aimed to evaluate whether LSD enhances liver reserve function in these patients.
methodsClinical data were collected over a 1-year follow-up after LSD, including the Child-Pugh score and class, albumin-bilirubin (ALBI) score and grade, indocyanine green retention rate at 15 min (ICG-R15), its plasma clearance rate (ICG-K), and its half-life (ICG-T1/2).
resultsAfter screening, 68 patients were included. At one year postoperatively, both Child-Pugh class and ALBI grade improved significantly after LSD (F = 4.52 and 7.48, respectively; both P < 0.001). Similarly, ICG-R15, ICG-K, and ICG-T1/2 all showed significant improvement compared to preoperative baseline values (F = 9.40, 69.43, 32.47, respectively; all P < 0.001). Moreover, compared to baseline, ICG-R15, ICG-K, and ICG-T1/2 demonstrated progressive and significant improvement from postoperative month (POM) 3 through POM 6 and POM 12 (all P < 0.001). Their maximum improvement was observed at POM 12, with changes of 42.3%, 25.8%, and 29.0%, respectively. These positive trends were consistently observed across their three ICG-R15-based subgroups (10% ≤ ICG-R15 < 20%, 20% ≤ ICG-R15 < 40%, and ICG-R15 ≥ 40%).
conclusionLSD enhances liver reserve function in patients with cirrhotic portal hypertension. This improvement may contribute to a better quality of life and greater tolerance for potential future therapies, such as those required in the event of hepatocellular carcinoma. The trial registration identifier at clinicaltrials.gov is NCT05325437.
Indexed as
Identifiers
42566007What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.